Impact ofEGFRmutations andKRASamino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact ofEGFRmutations andKRASamino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer
Authors
Keywords
-
Journal
Future Oncology
Volume 12, Issue 1, Pages 59-70
Publisher
Future Medicine Ltd
Online
2015-11-30
DOI
10.2217/fon.15.273
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcomes by Tumor Histology and KRAS Mutation Status After Lung Stereotactic Body Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer
- (2015) Raymond H. Mak et al. Clinical Lung Cancer
- EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation
- (2014) M. Wang et al. CANCER RESEARCH
- Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer
- (2013) James W. Welsh et al. JOURNAL OF CLINICAL ONCOLOGY
- A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non–Small Cell Lung Cancer Setting—IFCT/ERMETIC2 Project Part 1
- (2013) Michèle Beau-Faller et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients
- (2013) Shih-Hsin Hsiao et al. LUNG CANCER
- Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma
- (2013) T. Iuchi et al. LUNG CANCER
- Two Is Better Than One: Combining IGF1R and MEK Blockade as a Promising Novel Treatment Strategy Against KRAS -Mutant Lung Cancer
- (2013) Ron Chen et al. Cancer Discovery
- The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
- (2013) Ondrej Fiala et al. Cancer Genetics
- Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma
- (2013) HongQing Zhuang et al. Drug Design Development and Therapy
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- Lungs Don’t Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers
- (2012) Anna M. Varghese et al. Journal of Thoracic Oncology
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Tumour molecular profiling for deciding therapy—the French initiative
- (2012) Frédérique Nowak et al. Nature Reviews Clinical Oncology
- EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases
- (2012) Hsin-Lun Lee et al. Radiation Oncology
- Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
- (2011) M. C. Garassino et al. ANNALS OF ONCOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
- (2011) Paul W. Sperduto et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer
- (2011) Yaping Xu et al. LUNG CANCER
- Concordance between epidermal growth factor receptor status in primary non-small-cell lung cancer and metastases: a post-mortem study☆
- (2010) Stefan B. Watzka et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
- (2010) R. Porta et al. EUROPEAN RESPIRATORY JOURNAL
- Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer
- (2010) David R. Gandara et al. Journal of Thoracic Oncology
- EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
- (2010) A. F. Eichler et al. NEURO-ONCOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping
- (2009) M Beau-Faller et al. BRITISH JOURNAL OF CANCER
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
- (2009) Anurag Singh et al. CANCER CELL
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erlotinib Attenuates Homologous Recombinational Repair of Chromosomal Breaks in Human Breast Cancer Cells
- (2008) L. Li et al. CANCER RESEARCH
- Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response
- (2008) C.-H. Gow et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search